Page 1

May 6 , 2021 Adaptimmune TRANSFORMING T CELL THERAPY Adaptimmune Reports First Quarter Financial Results and Business Update - Initial SPEARHEAD - 1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA - independent TCR ( HIT ) targeting mesothelin at ASGCT - - Enrollment momentum in SURPASS and ADP - A2AFP clinical trials increased in Q1 - - Astellas nominates second target as part of allogeneic co - development and co- commercialization agreement - - Financial guidance confirmed : funded into early 2023 - - Conference call to be held today at 9:00 a.m. EDT ( 2:00 p.m. BST ) - PHILADELPHIA and OXFORD , United Kingdom , May 06 , 2021 ( GLOBE NEWSWIRE ) -- Adaptimmune Therapeutics plc ( Nasdaq : ADAP ) , a leader in cell therapy to treat cancer , today reported financial results for the first quarter ended March 31 , 2021 and provided a business update . " We will present initial data at ASCO from our SPEARHEAD - 1 trial that will support BLA submission in 2022. We have seen good enrollment in the SURPASS and ADP - A2AFP trials and will present data later this year , ” said Adrian Rawcliffe , Adaptimmune's Chief Executive Officer . " We continue to deliver against our ambitions laid out in our 2-2-5-2 strategic plan to bring products forward for clinical development and launch . At ASGCT next week , we will present preclinical data from our first HiT product targeting mesothelin . Results indicate that this HiT works as well or better than similar cell therapy constructs targeting the same antigen in in vitro killing assays as well as an animal model . " Upcoming confirmed data updates • Data from the Company's HiT mesothelin program , being co - developed with Astellas , to be presented at the American Society of Gene & Cell Therapy ( ASGCT ) , in a poster presentation that will be available on the conference's website May 11 at 8:00 a.m. EDT 。 Important progress towards achievement of preclinical pipeline milestones laid out in the Company's strategic five - year “ 2-2-5-2 ” product development plan presented at Investor Day in November 2020 。 Preclinical data validate that human T - cells expressing a TCR that targets mesothelin independent of peptide - HLA recognition , can kill human tumor cells 。 Presentation will include animal model data that demonstrate superiority of the Company's HiT targeting mesothelin over a comparator T - cell therapy construct targeting the same antigen in an in vivo tumor xenograft study